Our Pipeline
Satellos's pipeline of forazapadin clinical programs across Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy (FSHD).
Our Pipeline
Duchenne Muscular Dystrophy (DMD)
Program Name
Description
Preclinical
Phase 1
Phase 2
BASECAMP
Double-blind, placebo-controlled study of forazapadin (SAT-3247) in pediatric participants with DMD (NCT07287189)
Phase 2
TRAILHEAD
Open-label study of forazapadin in adults with DMD (NCT06867107)
Phase 2
Facioscapulohumeral Muscular Dystrophy (FSHD)
Program Name
Description
Preclinical
Phase 1
Phase 2
TRAVERSE (SAT-3247-CL-211)
Study of forazapadin in adults with FSHD is planned, with enrollment expected to begin in the fourth quarter of 2026.
Phase 2